Vir Bio技术股票：三期成功后估值合理？（纳斯达克：VIR）
· seekingalpha.com
完美三期ECLIPSE 1结果及与吉利德重要新合作后，Vir Bio技术仍为买入评级。在此了解更多关于VIR股票的信息。
About six months ago, I wrote an article on Vir Biotechnology, Inc. ( VIR ) following their massive $1.7 billion collaboration agreement with Astellas Pharma. M...